
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics NV demonstrates a strong potential for stock appreciation due to its promising pipeline of RNA-based therapeutics, particularly if the company advances its products into clinical stages sooner than projected and achieves pivotal proof of concept data in humans. The innovative Axiomer RNA base-editing platform is anticipated to generate significant clinical data, which could enhance the company's valuation. Additionally, management's assertion that the current cash position supports operations through mid-2027 provides a solid financial foundation for executing its development plans.
Bears say
ProQR Therapeutics NV reported a significant net loss of €12.2 million for the quarter, showing a marked decline from a loss of €2.7 million in the same period of the previous year, indicating worsening financial performance. The company's future is highly contingent on the outcomes of its Phase Ib/II/III studies, which carry the risk of negatively impacting shares based on their results. Furthermore, advancements in treatment methods for genetic diseases could potentially make ProQR's therapies non-competitive or obsolete, further complicating its market position.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares